

## Product datasheet for **TL500229V**

### Btg3 Mouse shRNA Lentiviral Particle (Locus ID 12228)

#### Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	Btg3 Mouse shRNA Lentiviral Particle (Locus ID 12228)
Locus ID:	12228
Synonyms:	ANA; tob; tob5
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	Btg3 - Mouse shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 <sup>7</sup> TU/ml.
RefSeq:	<a href="#">BC012705</a> , <a href="#">BC094027</a> , <a href="#">NM_001297747</a> , <a href="#">NM_009770</a> , <a href="#">NM_009770.1</a> , <a href="#">NM_009770.2</a> , <a href="#">NM_009770.3</a> , <a href="#">NM_001297747.1</a> , <a href="#">BC147656</a> , <a href="#">BC147662</a>
UniProt ID:	<a href="#">P50615</a>
Summary:	This gene encodes B cell translocation gene 3, a member of the BTG gene family. This family is defined by a conserved N-terminal domain, known to bind transcription factors, and a less conserved C-terminal domain. This protein is thought to have anti-proliferative properties, and may be involved in regulating the G1-S transition to suppress cell cycle progression. Mice deficient for this gene display an increased incidence of lung cancers, and many human lung cancer cells exhibit decreased levels of B cell translocation gene 3. Alternate splicing results in multiple transcript variants. A pseudogene of this gene is found on chromosome 17. [provided by RefSeq, Jul 2014]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <a href="mailto:techsupport@origene.com">techsupport@origene.com</a> . If you need a special design or shRNA sequence, please utilize our <a href="#">custom shRNA service</a> .



[View online »](#)

**Performance  
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at [techsupport@origene.com](mailto:techsupport@origene.com). Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).